The IBCG25 retreat will bring together global leaders in bladder cancer to advance two high-impact initiatives: • Biomarkers in Urothelial Cancer: Focused on identifying best practices for biomarker discovery and clinical application—from diagnosis and surveillance to treatment and trial endpoints. • IBCG Bladder Toxicity Index (IBCG-BTx): A comprehensive framework to measure bladder-specific toxicity across therapies, including radiation, immunotherapy, and surgery. This year's meeting will feature collaborative working sessions, invited presentations, and contributions from industry and advocacy partners. More details to follow.

Join us for the 4th annual AUA–IBCG Bladder Cancer Forum, featuring rapid-fire debates on key controversies in contemporary bladder cancer management. IBCG members from around the world will present both sides of pressing clinical questions, offering diverse perspectives and expert insights in a fast-paced, engaging format.  

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.